Total investments 26
Average round size 
$7M
The average size of a deal this fund participated in
Portfolio companies 22
Rounds per year 1.62
Lead investments 4
Follow on index
0.15How often the fund supports its portfolio startups at next rounds
Exits 2
Key employees Soon
Haidian, Beijing, China Related Funds
Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Fuho Capital:
Typical Co-investors
Fuho Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Fuho Capital:
Look at other 50 related and similar funds Collapse list ↓
| Fund Name | Location |
| Baring Private Equity Partners Espana | Community of Madrid, Madrid, Spain |
| BlueOrchard Finance S A | Geneva, Geneve, Switzerland |
| Camtech | California, Palo Alto, United States |
| CEJ Capital | Ibaraki Prefecture, Japan, Tsukuba |
| Ceres Global AG | Minnesota, Saint Louis Park, United States |
| Christiana Care Health Systems | Delaware, United States, Wilmington |
| Ginkgo Bioworks | Boston, Massachusetts, United States |
| Global PMX | - |
| HDFC ERGO General Insurance Company Limited | India, Maharashtra, Mumbai |
| Infinity Venture Capital | - |
| KBH Ventures | Austin, Texas, United States |
| NextGen Venture Partners | Baltimore, Maryland, United States |
| Peterson Group | China, Hong Kong, Hong Kong Island |
| Qbic Fund | Belgium, United States, Wisconsin |
| Strada Education Network | Indiana, Indianapolis, United States |
| Synergo Capital | Italy, Lombardy, Milan |
| Terada Warehouse | Chiyoda, Japan |
| Timesbole | China, Guangdong, Shenzhen |
| VIZIO | California, Irvine, United States |
| Wanyan Asset Management | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Leman Biotech | $7M | 18 Jun 2024 | Lausanne, Vaud, Switzerland | ||
Novamab | $27M | 07 Jun 2024 | - | ||
Hengsai Biological | $15M | 27 Nov 2023 | - | ||
Euregen Biopharma | 20 Oct 2023 | Suzhou, Jiangsu, China | |||
Intellective Bio | $77M | 05 Aug 2022 | Suzhou, Jiangsu, China | ||
DoYCan | 13 Jun 2022 | Guangzhou, Guangdong, China | |||
Resproly | 30 Apr 2022 | Xiangzhou District, Guangdong Province, China | |||
Xinling Pharmaceutical | $15M | 18 Mar 2022 | - | ||
Novamab | $15M | 12 Mar 2021 | - |
By posting comments on our website you confirm and acknowledge that:
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
To post a comment or write a complain, please sign in with LinkedIn
Review
- No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Do you represent Fuho Capital?
Get access to manage this page
Found incorrect info? Let us know!
Total investments 26
Average round size 7M
Rounds per year 1.62
Peak activity year 2015
Lead investments 4
Follow on index 0.15
Exits 2
Group Appearance index 0.81
Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Leman Biotech | $7M | 18 Jun 2024 | Lausanne, Vaud, Switzerland | ||
Novamab | $27M | 07 Jun 2024 | - | ||
Hengsai Biological | $15M | 27 Nov 2023 | - | ||
Euregen Biopharma | 20 Oct 2023 | Suzhou, Jiangsu, China | |||
Intellective Bio | $77M | 05 Aug 2022 | Suzhou, Jiangsu, China | ||
DoYCan | 13 Jun 2022 | Guangzhou, Guangdong, China | |||
Resproly | 30 Apr 2022 | Xiangzhou District, Guangdong Province, China | |||
Xinling Pharmaceutical | $15M | 18 Mar 2022 | - | ||
Novamab | $15M | 12 Mar 2021 | - |
